Page last updated: 2024-12-11

5-hydroxythalidomide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-hydroxythalidomide: do not confuse with 5'-hydroxythalidomide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5743568
CHEMBL ID182442
CHEBI ID168639
SCHEMBL ID15559573
MeSH IDM0540364

Synonyms (35)

Synonym
64567-60-8
5-hydroxythalidomide
2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisoindole-1,3-dione
CHEBI:168639
alpha-n-(4-hydroxyphthalimido)-glutarimide
(+/-)-hydroxythalidomide
CHEMBL182442
29v976c3cj ,
1h-isoindole-1,3(2h)-dione, 2-(2,6-dioxo-3-piperidinyl)-5-hydroxy-
unii-29v976c3cj
SCHEMBL15559573
phthalimide, n-(2,6-dioxo-3-piperidyl)-4-hydroxy-
5-hydroxy thalidomide, (+/-)-
5-hydroxy thalidomide
2-(2,6-dioxopiperidin-3-yl)-5-hydroxy-2,3-dihydro-1h-isoindole-1,3-dione
AT13473
2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisoindoline-1,3-dione
TQP0426
DTXSID40983186
5-hydroxy-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-1h-isoindole-1,3(2h)-dione
thalidomide-5-oh
HY-23095
EX-A3036
BCP33978
CS-0044368
mfcd24386541
AMY27672
Q27254447
A936391
BP-24501
2-(2,6-dioxo-3-piperidinyl)-5-hydroxy-1,3-isoindolinedione
SY233785
EN300-7564045
Z2508933762
AKOS040759765
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phthalimidesA dicarboximide that is phthalimide or derivatives obtained from it by the formal replacement of one or more hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID423805Antiangiogenic activity against VEGF-induced HUVEC assessed as tube area at 100 uM after 11 days by BCIP/NBT visualization assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
AID252970Percent cell proliferation of human leukemia cell line HL-60 at 1*E-5 M2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Cell differentiation inducers derived from thalidomide.
AID257636Inhibitory activity in HUVEC tube formation assay at 100 uM2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Angiogenesis inhibitors derived from thalidomide.
AID423812Cytotoxicity against human HS-Sultan cells assessed as cell viability at 100 ug/ml after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
AID423807Antiangiogenic activity against VEGF-induced HUVEC assessed as tube joint at 100 uM after 11 days after 11 days by BCIP/NBT visualization assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
AID423811Cytotoxicity against human IM9 cells assessed as cell viability at 100 ug/ml after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
AID423810Cytotoxicity against human MCF7 cells assessed as cell viability at 100 ug/ml after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
AID423809Cytotoxicity against human KB cells assessed as cell viability at 100 ug/ml after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
AID423808Antiangiogenic activity against VEGF-induced HUVEC assessed as tube path at 100 uM after 11 days after 11 days by BCIP/NBT visualization assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
AID251662Inhibitory activity against tubulin polymerization at 50 uM2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Tubulin-polymerization inhibitors derived from thalidomide.
AID423806Antiangiogenic activity against VEGF-induced HUVEC assessed as tube length at 100 uM after 11 days after 11 days by BCIP/NBT visualization assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
AID252627NBT positivity against human leukemia cell line HL-60 at 1*E-5 M2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Cell differentiation inducers derived from thalidomide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (30.77)29.6817
2010's4 (30.77)24.3611
2020's5 (38.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.13 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]